Navigation Links
Statin use decreases the risk of Barrett's esophagus
Date:7/23/2014

Bethesda, MD (July 23, 2014) Statins, a class of drugs commonly used to lower cholesterol levels, significantly reduce a patient's risk of developing Barrett's esophagus, according to a new study in Gastroenterology1, the official journal of the American Gastroenterological Association. Obese patients experienced the greatest level of risk reduction with statin use.

"Patients who received statins had a 43 percent reduction in the odds of having Barrett's esophagus compared to non-users," said study author Hashem B. El-Serag, MD, MPH, from the Houston VA Medical Center and Baylor College of Medicine, Houston, TX. "This is the first study to find a significantly lower risk of Barrett's esophagus with statin use, independent of other known risk factors. Further studies are needed to examine this association."

Researchers conducted a single-center, large case-control study of 303 Barrett's esophagus patients and 909 controls treated at the Michael E. DeBakey Veteran Affairs Medical Center in Houston, TX. They compared electronic pharmacy records during a 10-year period to ascertain medication use and evaluated the association between the use of statins and the risk of Barrett's esophagus. The findings indicate that statins may have a protective effect against the development of Barrett's esophagus. This association was independent of known risk factors, including age, race, gender, H. pylori infection and smoking status.

The protective effect of statins was especially significant among patients who were obese. Those with a body mass index greater than or equal to 30 had a 74 percent reduction in Barrett's esophagus.

Patients who had frequent gastroesophageal reflux disease symptoms had a 59 percent reduction in Barrett's esophagus odds. The researchers also found that patients who used statins for three or more years had higher risk reduction.

It is important to note that this study was conducted at a single-center VA medical center, where the patient population consisted mostly of older men, and so results may not be generalizable to a wider population. Also important, simvastatin was by far the most commonly prescribed statin in this study (94.3 percent), and, therefore, generalizability to other statins may be limited.

Statins are a class of drugs used to lower cholesterol levels. While statins have been associated with a reduced risk of esophageal cancer, this is one of the first studies to look at their effect on development of Barrett's esophagus.

Barrett's esophagus affects 1 to 2 percent of the general population and is the only known precancerous lesion for esophageal cancer. Barrett's esophagus increases the risk of developing this cancer by 10- to 55-fold compared with the general population. For more information on this condition, refer to AGA's medical position statement on the management of Barrett's esophagus.


'/>"/>

Contact: Rachel Steigerwald
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. Benefits of Widespread Statin Use Outweigh Risks: Study
2. Statins prevent cancer in heart transplant recipients
3. Statins May Help Prevent Enlarged Prostate: Study
4. Pivotal role for proteins -- from helping turn carbs into energy to causing devastating disease
5. Are Statins Less Helpful for Women?
6. Turning off key piece of genetic coding eliminates toxic effect of statins, SLU research finds
7. Statins Heart Benefits Outweigh Diabetes Risk: Study
8. Statins Wont Hurt, Might Even Help, Your Pancreas: Study
9. Statin Use Tied to Possible Boost in Cataract Risk
10. New Drug May Help Those Who Cant Take Statins
11. Looking for the anti-Alzheimers molecule -- A new approach to treating a devastating disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... continuing its traditions of innovation by partnering with college students at University of ... led the CU-Boulder senior level advertising campaigns class in the School of Journalism, ...
(Date:5/2/2016)... ... May 02, 2016 , ... Eating Recovery Center’s Insight Behavioral Health Center ... disorders, has rebranded its eating disorder program under a new name: Eating Recovery Center, ... on May 16. , To celebrate, ERC Chicago will host a ribbon-cutting ceremony ...
(Date:5/2/2016)... ... May 02, 2016 , ... “Engineering Bubbles,” an oil painting submitted ... ARRS Art Forum held recently at the Annual Meeting in Los Angeles. The first ... ARRS members and Annual Meeting attendees. , “Through art I hope to ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... for the 2016 Main Residency Match® (“the Match”), the system through which U.S. ... teaching institutions. A record-high 30,750 positions were placed in the 2016 Match, and ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Philip Shindler, ... with same day treatments. In the past, many necessary dental treatments could require multiple ... with multiple anesthetic shots and extra chair time. Not only could this be inconvenient, ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... April 27, 2016   ... Growth in Recurring Consumable Sales  Clinical sales ... Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, ... sales for the first quarter ended March 31, 2016 ... execution of its commercial strategy. First Quarter ...
(Date:4/27/2016)...   Zillion Group today announced the ... which specializes in live video consultation. Turning content, ... Zillion enables companies to realize the true potential ... control of their health. Zillion,s ... one-to-one, group and webcast scheduled or on-demand – ...
Breaking Medicine Technology: